BIRC5 and glioblastoma: Combination therapy with temozolomide and survivin augmentation through miR-138 increases the survival in GBM xenograft murine models compared with the use of temozolomide alone, suggesting a clinical benefit of survivin inhibition with standard chemotherapeutic agents for treating the malignancy.